Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$60 Mln
P/E Ratio
--
P/B Ratio
0.49
Industry P/E
--
Debt to Equity
0.32
ROE
-0.17 %
ROCE
-12.68 %
Div. Yield
0 %
Book Value
1.27
EPS
-0.23
CFO
$446.77 Mln
EBITDA
$888.22 Mln
Net Profit
$-567.23 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Assertio Therapeutics Inc (ASRT)
| -29.06 | -18.33 | -26.69 | -28.60 | -34.11 | -28.88 | -40.47 |
|
BSE Sensex*
| 2.06 | 2.90 | 5.96 | 8.31 | 12.01 | 20.26 | 11.38 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Assertio Therapeutics Inc (ASRT)
| -18.45 | -75.12 | 97.25 | 52.40 | -71.39 | -65.37 | -54.96 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.31 | 6,904.81 | -- | 38.11 | |
| 71.71 | 7,574.08 | 58.3 | 23.56 | |
| 59.16 | 11,448.88 | 394.4 | 0.76 | |
| 8.13 | 9,704.70 | -- | -3.24 |
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis,... including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois. Read more
Interim CEO & Director
Ms. Heather L. Mason
Interim CEO & Director
Ms. Heather L. Mason
Headquarters
Lake Forest, IL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Assertio Therapeutics Inc (ASRT) stood at $ 285 Mln as on 31-Dec-24
The share price of Assertio Therapeutics Inc (ASRT) is $0.62 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Assertio Therapeutics Inc (ASRT) has given a return of -34.11% in the last 3 years.
Assertio Therapeutics Inc (ASRT) has a market capitalisation of $ 60 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Assertio Therapeutics Inc (ASRT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Assertio Therapeutics Inc (ASRT) and enter the required number of quantities and click on buy to purchase the shares of Assertio Therapeutics Inc (ASRT).
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
The CEO & director of Ms. Heather L. Mason. is Assertio Therapeutics Inc (ASRT), and CFO & Sr. VP is Ms. Heather L. Mason.
There is no promoter pledging in Assertio Therapeutics Inc (ASRT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Assertio Therapeutics Inc (ASRT) | Ratios |
|---|---|
|
Return on equity(%)
|
-16.58
|
|
Operating margin(%)
|
-19.66
|
|
Net Margin(%)
|
-17.19
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Assertio Therapeutics Inc (ASRT) was $0 Mln.
$-0.01
(
